Abstract
Plasmodium vivax is the most widespread malaria species to infect human populations. P. vivax invades young red cells called reticulocytes to replicate and proliferate. An essential protein in parasite invasion is the Apical Membrane Antigen 1, PvAMA1, which forms the tight junction between parasite and red cell membrane through its interaction with Rhoptry Neck Protein 2, PvRON2. Here we report the identification of PvAMA1 nanobodies using phage display in combination with Sanger sequencing, next-generation sequencing and structure prediction tools. We show that these nanobodies bind with high affinities and across several different epitopes on PvAMA1. Several nanobodies recognize PvAMA1 in merozoites of late-stage schizonts and inhibit parasite invasion of red blood cells. These growth inhibitory nanobodies bind to conformational epitopes of PvAMA1 and most bind to a site distinct from a known potent human monoclonal antibody 826827. Crystal structures of two inhibitory nanobodies in complex with PvAMA1 show that they bind novel neutralizing epitopes which are outside the hydrophobic groove that contacts PvRON2. Furthermore, we show that two other PvAMA1 nanobodies also inhibit Plasmodium falciparum invasion. These results demonstrate the potential of PvAMA1 nanobodies to inhibit malaria parasite invasion across multiple Plasmodium species. Author Summary: Malaria parasites are exquisitely adapted for invasion and survival within human red blood cells. Merozoites are the form of the malaria parasites that invade red cells. Parasite invasion begins with initial attachment of the merozoite to the red blood cell surface, followed by tight junction formation between the parasite and the red blood cell membrane. Active invasion proceeds as the tight junction moves from the apical to posterior pole of the merozoite and pulls the parasite into the red blood cell. In Plasmodium vivax , PvAMA1 is critical for tight junction formation during parasite invasion. Here we describe the identification of nanobodies that bind to PvAMA1 at different sites using phage display combined with Sanger sequencing, next-generation sequencing and structure prediction approaches. We show that PvAMA1 nanobodies potently inhibit malaria parasite invasion in multiple Plasmodium species, demonstrating their potential to reduce malaria infection of red blood cells.
Funding Information
  • National Institutes of Health (R01AI143694)
  • Veterans Affairs Research Services (I01 BX001350)

This publication has 72 references indexed in Scilit: